Steven Leonard Chapman Sells 3,950 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,950 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $200.02, for a total transaction of $790,079.00. Following the completion of the sale, the chief executive officer directly owned 156,607 shares in the company, valued at approximately $31,324,532.14. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25.
• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total transaction of $881,499.84.

Natera Stock Performance

Shares of NTRA traded up $6.87 during trading hours on Tuesday, hitting $207.04. The stock had a trading volume of 1,542,969 shares, compared to its average volume of 1,162,477. The firm has a 50-day moving average price of $225.25 and a 200 day moving average price of $204.78. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm has a market capitalization of $29.34 billion, a price-to-earnings ratio of -135.32 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 16.71%. During the same quarter in the previous year, the company earned ($0.41) earnings per share. As a group, analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on NTRA shares. Robert W. Baird raised their price objective on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday. Evercore increased their target price on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Guggenheim boosted their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $253.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Reflection Asset Management acquired a new stake in shares of Natera in the fourth quarter valued at about $29,000. Palladiem LLC purchased a new stake in Natera during the 4th quarter valued at about $31,000. Horizon Investments LLC acquired a new stake in Natera in the 3rd quarter valued at about $32,000. Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.